Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis
- Conditions
- Non Alcoholic Steatohepatitis
- Interventions
- First Posted Date
- 2019-03-05
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Zydus Therapeutics Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03863574
- Locations
- πΊπΈ
Texas Liver Institute, San Antonio, Texas, United States
πΊπΈSouthern Therapy and Advanced Research (STAR) LLC, Jackson, Mississippi, United States
πΊπΈGastro One, Germantown, Tennessee, United States
Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD)
- First Posted Date
- 2018-08-21
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Zydus Therapeutics Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03639623
- Locations
- πΊπΈ
Virginia Commonwealth University, Richmond, Virginia, United States
Saroglitazar Magnesium 4 mg in the Treatment of NAFLD in Women With PCOS (EVIDENCES VII)
- Conditions
- Non-alcoholic Fatty Liver Disease in Women With PCOS
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Zydus Therapeutics Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT03617263
- Locations
- πΊπΈ
Zydus US002, San Francisco, California, United States
πΊπΈZydus US008, Aurora, Colorado, United States
πΊπΈZydus US005, Chandler, Arizona, United States
Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Zydus Therapeutics Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT03112681
- Locations
- πΊπΈ
California Liver Research Institute, Pasadena, California, United States
πΊπΈCarolinas Healthcare System, Charlotte, North Carolina, United States
πΊπΈSchiff Center for Liver Diseases/University of Miami, Miami, Florida, United States
Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride β₯500 mg/dL and β€1500 mg/dL
- Conditions
- Dyslipidemias
- Interventions
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Zydus Therapeutics Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT03097107
- Locations
- πΊπΈ
Herman Clinical Research, LLC, Suwanee, Georgia, United States
πΊπΈDrug Studies America, Marietta, Georgia, United States
πΊπΈRiver Birch Research Alliance LLC, Blue Ridge, Georgia, United States
Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis
- Conditions
- Nonalcoholic SteatohepatitisNon-Alcoholic Fatty Liver Disease
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Zydus Therapeutics Inc.
- Target Recruit Count
- 106
- Registration Number
- NCT03061721
- Locations
- πΊπΈ
Precision Research, San Diego, California, United States
πΊπΈCedars-Sinai Medical Center, Los Angeles, California, United States
πΊπΈCatalina Research Institute, Montclair, California, United States